Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PYX-201 |
Synonyms | |
Therapy Description |
PYX-201 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting the extra domain B (EDB) splice variant of fibronectin linked to Aur0101, which delivers the cytotoxic agent to tumor cells, potentially inducing tumor cell killing and inhibition of tumor growth (PMID: 36876967). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PYX-201 | PYX201|PYX 201 | PYX-201 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting the extra domain B (EDB) splice variant of fibronectin linked to Aur0101, which delivers the cytotoxic agent to tumor cells, potentially inducing tumor cell killing and inhibition of tumor growth (PMID: 36876967). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |